• On 24 August 2026, Tempus AI received FDA 510(k) clearance for Tempus ECG-PH, an AI tool that analyzes standard 12-lead ECGs for signs associated with pulmonary hypertension in symptomatic patients over 40 without a known history of the disease.
• This third FDA-cleared cardiovascular device extends Tempus AI’s AI-enabled diagnostics portfolio into pulmonary hypertension, a hard-to-diagnose condition affecting a meaningful share of older adults.
• We’ll now examine how this new FDA-cleared ECG-PH software, expanding Tempus AI’s cardiovascular portfolio, could influence its existing investment narrative.

AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Tempus AI Investment Narrative Recap

To own Tempus AI, you have to believe its AI and genomics platform can scale into a broader clinical decision support and data business, with improving economics despite current losses and a rich valuation. The new FDA clearance for ECG-PH reinforces the “dry lab” software thesis, but it does not obviously change the key near term swing factors: execution on reimbursement for advanced assays and the risk that AI tools remain under-monetized.

The most relevant recent announcement here is the August PRISM2 pathology foundation model update, which showed strong performance across diagnostics and outcome prediction. Together with ECG-PH, it underscores Tempus AI’s push to build a large library of multimodal, software-first tools that could support higher margin “dry lab” revenue, if reimbursement and adoption materialize in line with expectations.

Yet investors should also weigh how much depends on payors eventually funding AI-based decision support at scale, because if that stalls...

Tempus AI's narrative projects $2.6 billion revenue and $13.4 million earnings by 2029. This requires 22.0% yearly revenue growth and a $267.8 million earnings increase from -$254.4 million today.

Uncover how Tempus AI's forecasts yield a $62.64 fair value, a 11% downside to its current price.

Exploring Other Perspectives

Before this ECG-PH clearance, the most optimistic analysts were already penciling in about US$2.7 billion of revenue and a swing to positive earnings by 2029, which is far more bullish than consensus and assumes that AI based services and multimodal models become major profit engines, so it is worth asking whether this new FDA approval strengthens that view or highlights how differently you and others might see Tempus AI’s future.

Explore 8 other fair value estimates on Tempus AI - why the stock might be worth as much as 35% more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Tempus AI research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free Tempus AI research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Tempus AI's overall financial health at a glance.

Searching For A Fresh Perspective?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.
• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.